Hyoscine N-Butil Bromide
Phase 3Small molecule
Hyoscine N-Butil Bromide is one of 7 small molecule programs targeting Analgesic Efficacy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Analgesic Efficacy
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Ultram
WWim Janssens
Approved
Journavx
Vertex PharmaceuticalsPhase 3
Paracetamol
GSKPhase 3
Hyoscine N-Butil Bromide
AASST Fatebenefratelli Sacco
Phase 3
Acupan
YYonsei University
Preclinical
Oxycodone Hcl
PPurdue Pharma LP
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyoscine N-Butil Bromide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AASST Fatebenefratelli Sacco